R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study

Juan Criado-García, Francisco Fuentes, Cristina Cruz-Teno, Antonio García-Rios, Anabel Jiménez-Morales, Javier Delgado-Lista, Pedro Mata, Rodrigo Alonso, José López-Miranda, Francisco Pérez-Jiménez, Spanish Group for the Study of Familiar Hypercholesterolemia, Juan Criado-García, Francisco Fuentes, Cristina Cruz-Teno, Antonio García-Rios, Anabel Jiménez-Morales, Javier Delgado-Lista, Pedro Mata, Rodrigo Alonso, José López-Miranda, Francisco Pérez-Jiménez, Spanish Group for the Study of Familiar Hypercholesterolemia

Abstract

Background: Heterozygous Familial Hypercholesterolemia (FH) is a genetic disorder characterized by a high risk of cardiovascular disease. Certain polymorphisms of the factor VII gene have been associated with the development of coronary artery disease and there is a known association between factor VII levels and polymorphic variants in this gene. To date, no study has evaluated the association between factor VII and coronary artery disease in patients with FH.

Results: This case-control study comprised 720 patients (546 with FH and 174 controls). We determined the prevalence and allele frequencies of the R353Q polymorphism of factor VII, the plasma levels of factor VII antigen (FVII Ag) and whether they could be predictive factors for cardiovascular risk. 75% (410) of the patients with FH were RR, 23% (127) RQ and 1.6% (9) QQ; in the control group 75.3% (131) were RR, 21.3% (37) RQ and 3.4% (6) QQ (p = 0.32). No statistically significant associations were observed in the distribution of genotypes and allele frequencies between case (FH) and control groups. Nor did we find differences when we evaluated the relationship between the R353Q polymorphism and cardiovascular risk (including coronary disease, ischemic stroke and peripheral arterial disease), either in the univariate analysis or after adjustment for sex, age, arterial hypertension, body mass index, xanthomas, diabetes, smoking, HDLc and LDLc and lipid-lowering treatment. The FVII Ag concentrations behaved in a similar fashion, with no differences for the interaction between controls and those with FH (RR vs. RQ/QQ; p = 0.96). In the subgroup of patients with FH no association was found among cardiovascular disease, genotype and FVII Ag levels (RR vs. RQ/QQ; p = 0.97).

Conclusions: Our study did not find a direct relationship between cardiovascular risk in patients with Heterozygous Familial Hypercholesterolemia, the R353Q polymorphism of factor VII and FVII Ag levels.

References

    1. Goldstein JL. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle E, editor. New York: McGraw-Hill; 2001. Familial hypercholesterolemia; pp. 2863–913.
    1. Goldstein JL, Schrott HJ, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68. doi: 10.1172/JCI107332.
    1. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4:214–25. doi: 10.1038/ncpcardio0836. Review.
    1. Pérez-Jiménez F, Lista JD, Pérez-Martínez P, López-Segura F, Fuentes F, Cortés B, Lozano A, López-Miranda J. Olive and haemostasis: a review on its healthy effects. Public Health Nutr. 2006;9(8A):1083–8. Review.
    1. Mutanen M, Freese R. Fats, lipids and blood coagulation. Curr Opin Lipidol. 2001;12:25–29. doi: 10.1097/00041433-200102000-00005.
    1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Mechanisms of disease-the pathogenesis of coronary artery disease and the acute syndromes. N Engl J Med. 1992;326:242–50. doi: 10.1056/NEJM199201233260406.
    1. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti WR, North WR, Haineer AP, Stirling Y, Imeson JD, Thomson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet. 1986;2:533–7. doi: 10.1016/S0140-6736(86)90111-X.
    1. Heinrich J, Balleisen L, Schulte H, Assmann G, vandeLoo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from de PROCAAM study in healthy men. Arterioscler Thromb. 1994;14:54–9.
    1. Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol. 2006;26:2800–06. doi: 10.1161/01.ATV.0000247249.82030.94.
    1. Karatela RA, Sainani GS. Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease. Atherosclerosis. 2010;209:235–40. doi: 10.1016/j.atherosclerosis.2009.08.043.
    1. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000;102:2816–22.
    1. Eriksson-Berg M, Silveira A, Orth-Gomer K, hamsten A, Schenck-Gustafsson K. Coagulation factor VII in middle-aged women with and without coronary heart disease. Thromb Haemost. 2001;85:787–92.
    1. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb. 1991;11:540–6.
    1. Bernardi F, Arcieri P, Bertina RM, Chiarotti F, Corral J, Pinotti M, Prydz H, Samama M, Sandset PM, Strom R, García VV, Mariani G. Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between Northern and southern European populations. Arterioscler Thromb Vasc Biol. 1997;17:2548–53.
    1. Mtiraoui N, Aboud N, Bouraoui H, Haizem S, Gris JC, Busson M, Tamim H, Almawi WY, Mahjoub T. Reduction in coagulation factor VII plasma levels by R353Q but not the -323P0/10 promoter polymorphism in healthy Tunisians. Am J Hematol. 2005;79:11–6. doi: 10.1002/ajh.20328.
    1. Kathiresan S, Yang Q, Larson MG, Camargo AL, Tofler GH, Hirschhorn JN, Gabriel Sb, O'Conell CJ. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Thromb Vasc Biol. 2006;26:1405–12. doi: 10.1161/01.ATV.0000222011.13026.25.
    1. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribution about one third of the factor VII levels variation in plasma. Arterioscler Thromb Vasc Biol. 1996;16:72–6.
    1. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774–80. doi: 10.1056/NEJM200009143431104.
    1. Lacoviello L, DiCastelnuovo A, de Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M. Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79–85. doi: 10.1056/NEJM199801083380202.
    1. Shikomata K, Kondo T, Ohno M, Takeshita K, Inden Y, Lino S, Saito H, Hirai M. Effects of coagulation Factor VII polymorphisms on the coronary artery disease in Japanese: Factor VII polymorphism and coronary disease. Thromb Res. 2002;15:493–8.
    1. Geng X, Jin GD, Fu GS, Ji MA, Shann J, Wang JA. Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography. J Zhejiang Univ Sci. 2003;4:369–73. doi: 10.1631/jzus.2003.0369.
    1. Ogawa M, Abe S, Biro S, Saigo M, Kihara T, Setoyama S, Matsuoka T, Toda H, Torii H, Atsuchi Y, Toyama Y, Tateishi S, Minagoe S, Maruyama I, Tei C. R353Q polymorphism, activated factor VII, and risk of premature myocardial infarction in Japanese men. Circ J. 2004;68:520–25. doi: 10.1253/circj.68.520.
    1. Jeffery S, Poliniecki J, Leatham E, Bevan D, Ireson N, Talbot S, Cole D, Kaski JC. A protective contribution of the Q allele of the R353Q polymorphism of the factor VII gene in individuals with cronic stable angina? Int J Cardiol. 2005;28:395–9. doi: 10.1016/j.ijcard.2004.07.013.
    1. Fujimaki T, Kato K, Yoshida T, Oguri M, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nishigaki Y, Tanaka M, Nozawa Y, Kimura G, Yamada Y. Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost. 2009;101:963–68.
    1. Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln (353) polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a Strong indicator of MI risk in the ECTIM study. Atherosclerosis. 1996;119:119–27. doi: 10.1016/0021-9150(95)05638-6.
    1. Batalla A, Alvarez R, Reguero JR, Gonzalez P, Alvarez V, Cubero GL, Cortina A, Coto E. Lack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men. Int J Cardiol. 2001;80:209–12. doi: 10.1016/S0167-5273(01)00496-X.
    1. Zheng Y, Liu E, Higgins J, Keavney BD, Lowe GD, Danesh. Seven haemostatic polymorphisms in coronary disease: meta-analysis of 66155 cases and 91397 controls. Lancet. 2006;367:651–58. doi: 10.1016/S0140-6736(06)68263-9.
    1. Maguire JM, Thakkinstian A, Sturm J, Levi C, Lincz L, Parsons M, Whyte S, Attia J. Polymorphisms in platelet glycoprotein 1bα and factor VII and risk of ischemic stroke: a meta-analysis. Stroke. 2008;39:1710–16. doi: 10.1161/STROKEAHA.107.507228.
    1. WHO. Human Genetics Program. Familial hypercholesterolaemia, a global prospective. Ginebra: WHO; 1999.
    1. Simera I, Mother D, Hirst A, Hoey K, Schultz KF, Altman DG. Transparent and accurate reporting increases reliability and impact of your research: reporting guidelines and the EQUATOR Network. BMC Med. 2010;26:8–24.
    1. Simera I, Mother D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35–53. doi: 10.1111/j.1365-2362.2009.02234.x. Review.
    1. World Health Organization Cardiovascular Diseases Unit. WHO MONICA Project: MONICA Manual. Geneva: World Health Organization; 1990.
    1. Lindman AS, Pedersen JI, Arneses H, Hjerkin EM, Veire∅d MB, Prydz H, Seljeflot I. Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease. Thromb Res. 2004;113:57–65. doi: 10.1016/j.thromres.2004.02.001.
    1. Baena Díez JM, del Val García JL, Tomás Pelegrina J, Martínez Martínez JL, Martín Peñacoba R, González Tejón I, Raidó Quintana EM, Pomares Sajkiewicz M, Altés Boronat A, Alvarez Pérez B, Piñol Forcadell P, Rovira España M, Oller Colom M. Cardiovascular disease epidemiology and risk factors in primary care. Rev Esp Cardiol. 2005;58:367–373.
    1. Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O, Galiana J, Figueras R, Diaz JL, Gomez-Enterría P, Mauri M, Piedecausa M, Irigoyen L, Aguado R, Mata P. Spanish Familial Hypercholesterolaemia Group. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008;200:315–21. doi: 10.1016/j.atherosclerosis.2007.12.024.
    1. López-Miranda J, Badimon L, Bonanome A. Monounsatured fat and cardiovascular risk. Nutr Rev. 2006;64:S2–S12.
    1. Gómez P, Fernández de la Puebla RA, Castro P, López-Miranda J, Marín C, Fuentes F, Pérez-Martínez P, Velasco F, Moreno JA, Torres A, Pérez-Jiménez F. Effect of the Mediterranean diet on casting concentrations of activated factor VII in healthy persons. Rev Esp Cardiol. 2005;58:285–9.
    1. de Sauge Noltin PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ. Prevalence and significance of cardiovascular risk in a large cohort of patients with familial hypercholesterolaemia. J Intern Med. 2003;253:161–8. doi: 10.1046/j.1365-2796.2003.01070.x.
    1. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106:3031–6. doi: 10.1161/01.CIR.0000041253.61683.08.
    1. Civeira F, Castillo S, Alonso R, Meriño-Ibarra E, Cenarro A, Artied M, Martín-Fuentes P, Ros E, Pocoví M, Mata P. Spanish Familial Hypercholesterolemia Group. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol. 2005;25:1960–5. doi: 10.1161/01.ATV.0000177811.14176.2b.
    1. van Aalst-Cohen ES, Jansen EC, Tanck MW, Defesche JC, Trip MD, Lansberg PJ, Stalenhoef AF, Kastelein JJ. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27:2240–6. doi: 10.1093/eurheartj/ehl113.
    1. Oosterver DM, Vermissen J, Yazdanpanah M, Defesche JC, Kastelein JJ, Sijbrands EJ. The risk of tendon xanthomas in familial hypercholesterolemia by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein pathway. Eur Heart J. 2010;31:1007–12. doi: 10.1093/eurheartj/ehp538.
    1. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA. Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43:943–9. doi: 10.1136/jmg.2006.038356.
    1. Feng DL, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Johnstone MT, Muller JE, D'Agostino RB, Levy D, Lindpaintner Ket. Factor VII polymorphism, factor VII levels, and prevalent cardiovascular disease-the Framingham heart study. Arterioscler Thromb Vasc Biol. 2000;20:593–600.
    1. Lee AJ, Fowkes FGR, Lowe GDO, Connor Jm, Rumely A. Fibrinogen, factor VII and PAI-1 genotypes and the risk at coronary and peripheral atherosclerosis: Edinburgh artery study. Thromb Haemost. 1999;81:553–60.
    1. Van der Krabben MD, Rosendaal FR, Van der Bom JG, Doggen CJ. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost. 2008;6:720–5. doi: 10.1111/j.1538-7836.2008.02930.x.
    1. Wu AHB, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol. 2001;87:1361–6. doi: 10.1016/S0002-9149(01)01553-3.
    1. Rubattu S, Di Angelantonio E, Nitsch D, Gigante B, Zanda B, Stanzione R, Evangelista A, Pirisi A, Rosati G, Volpe M. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost. 2005;93:1095–100.
    1. Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, Defesche JC, Kastelein JJ. Genetic determinants of cardiovascular risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2005;25:1475–81. doi: 10.1161/01.ATV.0000168909.44877.a7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren